DRMA: Prakiraan wutah bathi kanggo taun ngarep Dermata Therapeutics Inc

The assessment of the annual EPS growth for the next period reflects a lack of current sales due to the FDA clinical testing stage for Dermata Therapeutics (DRMA). The foundation for success is based on Spongilla microneedles and raw material scaling, while unique extended-release solutions ensure premium pricing power. This indicator's trend smooths out market noise, with the metric holding around 34.10, signaling a shift in expert expectations.

DRMA: Prakiraan wutah bathi resik saben saham ing taun ngarep Dermata 04.07.2022 - 15.11.2026

Rincian analitis perusahaan Dermata Therapeutics

- rega lan prakiraan konsensus rega:

Bagan rega Dermata Therapeutics, Inc.|DRMA - Prakiraan gabungan firma investasi

- informasi kapitalisasi pasar:

Kapitalisasi pasar Dermata Corp|DRMA - Nilai Bisnis

- indikator kapitalisasi buku:

Nilai Buku saben Saham Dermata Therapeutics|DRMA - Ekuitas Perusahaan|Rasio Nilai Pasar marang Nilai Buku dermatarx.com|DRMA - Nilai Agregat Aset

- statistik kawajiban utang lan likuiditas:

Utang marang Ekuitas Dermata Therapeutics|DRMA - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Dermata Therapeutics Inc|DRMA - Gunggung utang perusahaan|Utang marang nilai buku Dermata Therapeutics|DRMA - Gedhene kewajiban jangka dawa|Utang jangka cendhak perusahaan Dermata Therapeutics|Indikator likuiditas cepet dermatarx.com

- informasi bathi lan kelipatan valuasi:

DRMA - Bathi pungkasan|Bathi mangsa ngarep Dermata Therapeutics|DRMA - Rasio rega pasar marang bathi resik|Pangali Forward P/E Dermata Therapeutics, Inc.|DRMA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA Dermata Therapeutics|DRMA - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Dermata Therapeutics|DRMA - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan dermatarx.com|DRMA - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Dermata Therapeutics

- data total pendapatan lan volume dodolan:

DRMA - Pendapatan tahunan perusahaan|Prakiraan volume dodolan Dermata Therapeutics Inc|DRMA - Rega marang dodolan|Multiplikator forward rega marang pendapatan Dermata Therapeutics, Inc.

Analisis dhasar perusahaan:Dermata

For Dermata Therapeutics (DRMA), which is developing targeted therapies for skin diseases, this indicator reflects market consensus expectations for the change in earnings per share (EPS) next year. By analyzing the projected EPS trend for the coming year, investors assess the speed at which the company monetizes its clinical successes, which determines business resilience amid the reallocation of capital across biopharmaceutical assets.

Pesaing langsung